Listed on Two Prestigious Rankings
Recently, Matwings has achieved successive milestones in the biomedical industry with two major authoritative recognitions. In late October 2025, our company was selected for the 2025 China Top 100 Biomedical Leaders list and included in the Future Explorer Enterprises cohort. Following this, it was honored on the 14th Five-Year Plan China Top 100 High-Quality Suppliers in the Pharmaceutical Industry list at the end of November.
These two honors are launched respectively by the Shanghai Biomedical Science and Technology Industry Promotion Center and E Pharmaceutical Manager, an influential thought leadership platform in the pharmaceutical sector. The selections aim to identify outstanding enterprises excelling in China’s pharmaceutical innovation and supply chain collaboration.
01. 2025 China Top 100 Biomedical Leaders
Jointly organized by the Shanghai Biomedical Science and Technology Industry Promotion Center and multiple institutions, the 2025 China Top 100 Biomedical Leaders list benchmarks leading enterprises across biomedicine, medical devices and digital healthcare.
Backed by its innovative strength in AI-driven biomedical R&D and global layout strategy, Matwings was successfully shortlisted in the Future Explorer List, underscoring its leading edge in original technological innovation and global vision.
02. 14th Five-Year Plan China Top 100 High-Quality Suppliers in the Pharmaceutical Industry
This list focuses on outstanding suppliers across the pharmaceutical industrial chain that excel in technology expertise, quality compliance and industrial collaboration.
With its self-developed general AI protein design large model AIACCLBIO®, as well as outstanding performance in innovation capability and industrial synergy, Matwings has earned recognition from the review committee. The honor reflects the company’s increasingly important supporting role within the pharmaceutical supply chain.
Matwings centers on its general AI protein design large model AIACCLBIO®, providing AI-empowered drug R&D and protein design services for the biomedical industry. Matwings has gradually formed a business model centered on joint development and supplemented by technical services, and has secured substantive pipeline orders in practice, further clarifying its positioning within the biomedical industrial chain.
Notably, amid the 2025 wave of China’s innovative pharmaceutical global expansion, Matwings has achieved a major breakthrough. Matwings entered into an innovative biopharmaceutical pipeline collaboration agreement with a world-leading U.S. biotechnology firm founded by top entrepreneurs in the life sciences sector. Under the agreement, Matwings is entitled to commercial returns including upfront development payments, development milestone payments, and product commercialization proceeds, as well as additional potential licensing revenue.
This collaboration not only marks Matwings’s official entry into the global strategic market, but also signals that AI technology is comprehensively driving biopharmaceutical R&D into a new development stage.
